Session » (1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

Date: Monday, October 27, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 1395

A Comparative Study of Yao Syndrome and Primary Sjögren’s Syndrome

10:30AM-12:30PM: Abstract Number: 1376

A Systematic Literature Review on the Economic Burden of Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1391

Assessment of Anti-SSA/Ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)

10:30AM-12:30PM: Abstract Number: 1389

Association Of Dry Eye Severity With Salivary Flow In Patients With Primary Sjögren’s Syndrome

10:30AM-12:30PM: Abstract Number: 1400

Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease

10:30AM-12:30PM: Abstract Number: 1394

Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States

10:30AM-12:30PM: Abstract Number: 1392

Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers

10:30AM-12:30PM: Abstract Number: 1397

Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.

10:30AM-12:30PM: Abstract Number: 1386

Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.

10:30AM-12:30PM: Abstract Number: 1385

Characterizing Isolated Dryness Phenotypes in Sjögren’s Syndrome

10:30AM-12:30PM: Abstract Number: 1390

Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome

10:30AM-12:30PM: Abstract Number: 1387

Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network

10:30AM-12:30PM: Abstract Number: 1404

Higher cardiovascular risk and lymphoma development in primary Sjögren’s Syndrome with extraglandular involvement

10:30AM-12:30PM: Abstract Number: 1377

Humanistic Burden of Sjögren’s Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality-of-Life

10:30AM-12:30PM: Abstract Number: 1396

Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1382

Interstitial lung disease in primary sjögren syndrome: pathochrony, seronegative cases, and Risk of progressive pulmonary fibrosis

10:30AM-12:30PM: Abstract Number: 1383

Obesity in Primary Sjogren’s Disease

10:30AM-12:30PM: Abstract Number: 1380

Phenotyping Neuropathic Pain in Sjögren’s Disease: A Cluster-Based Approach

10:30AM-12:30PM: Abstract Number: 1388

Positive predictive value of various diagnostic codes for the classification of primary Sjӧgren’s syndrome

10:30AM-12:30PM: Abstract Number: 1378

Prevalence of Central Nervous System Manifestations in Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1393

Prevalence of Sjögren’s Disease in the United States – A Retrospective Cohort Study Among a Commercially Insured Population (2019-2023)

10:30AM-12:30PM: Abstract Number: 1401

Real World Treatment Patterns and Health Care Resource Use in Patients With Newly Diagnosed Sjögren’s Disease (SjD) in the United States

10:30AM-12:30PM: Abstract Number: 1379

Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort

10:30AM-12:30PM: Abstract Number: 1398

Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health

10:30AM-12:30PM: Abstract Number: 1381

Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes

10:30AM-12:30PM: Abstract Number: 1399

Significance of Antiphospholipid Antibodies in Patients with Sjogren’s Disease

10:30AM-12:30PM: Abstract Number: 1384

Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease

10:30AM-12:30PM: Abstract Number: 1403

Treatment of sleep apnoea syndrome in patients with primary Sjögren’s disease improves symptoms and activity of disease

10:30AM-12:30PM: Abstract Number: 1402

Understanding Fatigue Through Patients’ Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren’s Disease

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].